Phase 2 N=154 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Seizures
Primary: Response Ratio (RRatio) — -24.06; -22.45; -25.90; -24.19 RRatio — p==0.986
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Focal Electroconvulsive Therapy for Depression
Major Depressive Disorder
Primary: Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item. — 5 Participants
Phase 2 N=67 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Epilepsy, Focal Seizures, Partial Seizures
Primary: Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment — -0.43; -0.58 log(seizure/28 days) — p=0.5053
Phase 3 N=240 RNS® System Pivotal Study
Epilepsy
Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE
Phase 2 N=31 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
Epilepsy, Partial
Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change
N/A N=3 Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
Mesial Temporal Lobe Epilepsy
Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants
N/A N=31 Cognitive Effects of Treatment of Interictal Discharges
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
N/A N=11 Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)
Epilepsies, Partial
Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants
Phase 3 N=71 An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
Epilepsy · Partial Onset Seizures
Primary: Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation…
Phase 3 N=768 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Epilepsy
Primary: Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration — 22.8; 23.2; 0 Percentage of…
Phase 3 N=91 Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)
Partial Onset Seizures
Primary: Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel — 63.0 percentage…
Phase 2 N=59 Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
Epilepsy, Partial
Primary: Percent Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit and Overall by Period — -26.07; -32.05; -42.22; -31.67 percentage…
Phase 4 N=102 A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
Epilepsy With Partial On-set Seizures
Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants
N/A N=5 Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
N/A N=17 High Frequency Oscillation in Pediatric Epilepsy Surgery
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants
N/A N=17 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Phase 3 N=180 Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Phase 2 N=411 Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
Drug-resistant Epilepsy · Focal-Onset Seizures
Primary: Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period — -0.27585; -0.46424; -0.48804; -0.48960 loge…
Phase 2 N=12 Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Glioma, Malignant · Surgery · Seizures
Primary: Peritumoral HFO Rate — 2.5; 1.4 HFOs per minute
Phase 4 N=106 Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
Epilepsy
Primary: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization — 80.0 percentage of participants
Phase 4 N=52 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
Partial Epilepsy
Primary: Change in Epworth Sleepiness Scale Score From Baseline to Visit 4 — -1.2; -1.1 Units on a scale — p=0.027
Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
Phase 3 N=64 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
Epilepsy
Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240
Phase 3 N=249 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Epilepsy
Primary: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. — 39.5; 21.65 Percent…
Phase 2 N=222 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001
Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures
Partial Seizures
Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants
Phase 3 N=130 Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Epilepsy
Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants
Phase 3 N=207 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Partial Seizures With or Without Secondary Generalization · Epilepsy
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 88.9; 95.5; 100; 94.1 percentage of participants